Juvisy sur Orge, France Clinical Trials

A listing of Juvisy sur Orge, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 76 clinical trials
featured
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 (formerly MGA012) in Patients with Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every two or four weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors.  The study consists of …

primary cancer
cancer
measurable disease
endometrial carcinoma
Institute Gustave Roussy (IGR)
 (6.8 away) Contact site
  • 229 views
  • 14 Dec, 2020
  • +15 other locations
Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors

The study will determine the recommended Phase 2 dose (RP2D) of ABBV-151 administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-151 alone and in combination with budigalimab. The study will consist of 2 phases: dose escalation …

Institut Gustave Roussy /ID# 218668
 (6.8 away) Contact site
  • 17 views
  • 31 May, 2021
  • +37 other locations
A Study to Evaluate the Reactogenicity Safety Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) Viral Vector Vaccines and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection.

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.

vaccination
vaccine therapy
hepatitis b surface
chronic hepatitis
cirrhosis
GSK Investigational Site
 (7.5 away) Contact site
  • 16 views
  • 05 Jun, 2021
  • +33 other locations
Investigating Safety Tolerability Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

Research Site
 (6.8 away) Contact site
  • 16 views
  • 02 Jun, 2021
  • +19 other locations
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer

Institut Gustave Roussy
 (7.0 away) Contact site
  • 5 views
  • 25 May, 2021
  • +33 other locations
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.

Novartis Investigative Site
 (6.8 away) Contact site
  • 0 views
  • 12 Jun, 2021
  • +33 other locations
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Gustave Roussy /ID# 215865
 (7.2 away) Contact site
  • 22 views
  • 27 Jan, 2021
  • +41 other locations
Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer

To evaluate the safety and tolerability of AMG 199 in adult subjects with MUC17-positive gastric and gastroesophageal junction cancer and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Institut Gustave Roussy
 (6.2 away) Contact site
  • 7 views
  • 13 Jun, 2021
  • +38 other locations
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

A phase 1, randomized, placebo-controlled, double-blind, dose escalation trial combining single-ascending dose and multiple-ascending dose phases of NI006 or placebo, followed by an open-label extension phase in subjects with Amyloid Transthyretin Cardiomyopathy (ATTR-CM).

H pital Henri Mondor
 (7.7 away) Contact site
  • 0 views
  • 15 May, 2021
  • +6 other locations
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Research Site
 (7.0 away) Contact site
  • 1 views
  • 03 Jun, 2021
  • +7 other locations